{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T12:54:54Z","timestamp":1773147294356,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1038\/nrclinonc.2009.90","type":"journal-article","created":{"date-parts":[[2009,7,31]],"date-time":"2009-07-31T10:47:37Z","timestamp":1249037257000},"page":"488-492","source":"Crossref","is-referenced-by-count":19,"title":["Eleven years disease-free: role of chemotherapy in metastatic BRCA2-related breast cancer"],"prefix":"10.1038","volume":"6","author":[{"given":"Fleur","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yael B.","family":"Kushner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Langleben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William D.","family":"Foulkes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BFnrclinonc200990_CR1","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.ijrobp.2008.05.031","volume":"73","author":"F Huang","year":"2009","unstructured":"Huang, F., Alrefae, M., Langleben, A. & Roberge, D. Prophylactic cranial irradiation in advanced breast cancer: a case for caution. Int. J. Radiat. Oncol. Biol. Phys. 73, 752\u2013758 (2009).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"BFnrclinonc200990_CR2","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1200\/JCO.2005.10.202","volume":"23","author":"WP Peters","year":"2005","unstructured":"Peters, W. P.  et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J. Clin. Oncol. 23, 2191\u20132200 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc200990_CR3","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1200\/JCO.2002.05.121","volume":"20","author":"DA Berry","year":"2002","unstructured":"Berry, D. A.  et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1\/BRCA2, and prevalence of other breast cancer susceptibility genes. J. Clin. Oncol. 20, 2701\u20132712 (2002).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc200990_CR4","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrc1431","volume":"4","author":"SA Narod","year":"2004","unstructured":"Narod, S. A. & Foulkes, W. D. BRCA1 and BRCA2, 1994 and beyond. Nat. Rev. Cancer 4, 665 (2004).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnrclinonc200990_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/01.pas.0000213351.49767.0f","volume":"31","author":"AL Bane","year":"2007","unstructured":"Bane, A. L.  et al. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am. J. Surg. Pathol. 31, 121\u2013128 (2007).","journal-title":"Am. J. Surg. Pathol."},{"key":"BFnrclinonc200990_CR6","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ejca.2006.07.019","volume":"43","author":"FP Liebens","year":"2007","unstructured":"Liebens, F. P., Carly, B., Pastijn, A. & Rozenberg, S. Management of BRCA1\/2 associated breast cancer: a systematic qualitative review of the state of knowledge in 2006. Eur. J. Cancer 43, 238\u2013257 (2007).","journal-title":"Eur. J. Cancer"},{"key":"BFnrclinonc200990_CR7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10689-005-2832-5","volume":"5","author":"WD Foulkes","year":"2006","unstructured":"Foulkes, W. D. BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam. Cancer 5, 135\u2013142 (2006).","journal-title":"Fam. Cancer"},{"key":"BFnrclinonc200990_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa070608","volume":"357","author":"G Rennert","year":"2007","unstructured":"Rennert, G.  et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N. Engl. J. Med. 357, 115\u2013123 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc200990_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10689-006-9112-x","volume":"6","author":"T Pal","year":"2007","unstructured":"Pal, T., Permuth-Wey, J., Kapoor, R., Cantor, A. & Sutphen, R. Improved survival in BRCA2 carriers with ovarian cancer. Fam. Cancer 6, 113\u2013119 (2007).","journal-title":"Fam. Cancer"},{"key":"BFnrclinonc200990_CR10","first-page":"1120","volume":"58","author":"A Husain","year":"1998","unstructured":"Husain, A., He, G., Venkatraman, E. S. & Spriggs, D. R. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res. 58, 1120\u20131123 (1998).","journal-title":"Cancer Res."},{"key":"BFnrclinonc200990_CR11","first-page":"580","volume":"25","author":"T Petit","year":"2007","unstructured":"Petit, T.  et al. Are BRCA1 mutations a predictive factor for anthracycline-based neoadjuvant chemotherapy response in triple-negative breast cancers? [abstract]. ASCO Meeting Abstracts 25, 580 (2007).","journal-title":"ASCO Meeting Abstracts"},{"key":"BFnrclinonc200990_CR12","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1038\/4511066a","volume":"451","author":"DM Livingston","year":"2008","unstructured":"Livingston, D. M. & Silver, D. P. Cancer: crossing over to drug resistance. Nature 451, 1066\u20131067 (2008).","journal-title":"Nature"},{"key":"BFnrclinonc200990_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0305-7372(03)00139-7","volume":"30","author":"MP Decatris","year":"2004","unstructured":"Decatris, M. P., Sundar, S. & O'Byrne, K. J. Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer Treat. Rev. 30, 53\u201381 (2004).","journal-title":"Cancer Treat. Rev."},{"key":"BFnrclinonc200990_CR14","unstructured":"Breakthrough Breast Cancer & Cancer Research UK Genetic Breast Cancer Trial: A randomised phase II pilot trial of carboplatin compared to docetaxel for patients with metastatic genetic breast cancer [online], \n                    http:\/\/www.geneticbreastcancertrial.usilu.net\/Home.asp\n                    \n                   (2008)."},{"key":"BFnrclinonc200990_CR15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s10549-007-9600-1","volume":"108","author":"T Byrski","year":"2008","unstructured":"Byrski, T.  et al. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res. Treat. 108, 289\u2013296 (2008).","journal-title":"Breast Cancer Res. Treat."},{"key":"BFnrclinonc200990_CR16","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/sj.bmt.1705366","volume":"37","author":"DT Vogl","year":"2006","unstructured":"Vogl, D. T. & Stadtmauer, E. A. High-dose chemotherapy and autologous hematopoietic stem cell transplantation for metastatic breast cancer: a therapy whose time has passed. Bone Marrow Transplant. 37, 985\u2013987 (2006).","journal-title":"Bone Marrow Transplant."},{"issue":"Suppl. 1","key":"BFnrclinonc200990_CR17","first-page":"S5","volume":"106","author":"DA Berry","year":"2007","unstructured":"Berry, D. A.  et al. High-dose chemotherapy with autologous stem-cell support versus standard-dose chemotherapy: meta-analysis of individual patient data from 15 randomized adjuvant breast cancer trials [abstract 11]. Breast Cancer Res. Treat. 106 (Suppl. 1), S5 (2007).","journal-title":"Breast Cancer Res. Treat."},{"key":"BFnrclinonc200990_CR18","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/jnci\/djn143","volume":"100","author":"RS Tuma","year":"2008","unstructured":"Tuma, R. S. End of high-dose chemotherapy for high-risk breast cancer patients? J. Natl Cancer Inst. 100, 618\u2013619 (2008).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc200990_CR19","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1002\/cncr.21906","volume":"106","author":"EO Hanrahan","year":"2006","unstructured":"Hanrahan, E. O.  et al. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years. Cancer 106, 2327\u20132336 (2006).","journal-title":"Cancer"},{"key":"BFnrclinonc200990_CR20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.bbmt.2005.10.009","volume":"12","author":"JJ Vredenburgh","year":"2006","unstructured":"Vredenburgh, J. J.  et al. Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone. Biol. Blood Marrow Transplant. 12, 195\u2013203 (2006).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"BFnrclinonc200990_CR21","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1097\/01.cad.0000180122.24031.13","volume":"16","author":"HJ Stemmler","year":"2005","unstructured":"Stemmler, H. J.  et al. Lasting remission following multimodal treatment in a patient with metastatic breast cancer. Anticancer Drugs 16, 1135\u20131137 (2005).","journal-title":"Anticancer Drugs"},{"key":"BFnrclinonc200990_CR22","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1200\/JCO.1996.14.8.2197","volume":"14","author":"PA Greenberg","year":"1996","unstructured":"Greenberg, P. A.  et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J. Clin. Oncol. 14, 2197\u20132205 (1996).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc200990_CR23","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","volume":"27","author":"RE Coleman","year":"2001","unstructured":"Coleman, R. E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev. 27, 165\u2013176 (2001).","journal-title":"Cancer Treat. Rev."},{"key":"BFnrclinonc200990_CR24","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1056\/NEJMoa0806285","volume":"360","author":"M Gnant","year":"2009","unstructured":"Gnant, M.  et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360, 679\u2013691 (2009).","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 1","key":"BFnrclinonc200990_CR25","doi-asserted-by":"publisher","first-page":"I27","DOI":"10.1093\/annonc\/mdh654","volume":"15","author":"P Marchetti","year":"2004","unstructured":"Marchetti, P.  et al. Reducing breast cancer incidence in familial breast cancer: overlooking the present panorama. Ann. Oncol. 15 (Suppl. 1), I27\u2013I34 (2004).","journal-title":"Ann. Oncol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2009.90.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2009.90","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2009.90.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:03:49Z","timestamp":1684469029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2009.90"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["BFnrclinonc200990"],"URL":"https:\/\/doi.org\/10.1038\/nrclinonc.2009.90","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}